An interventional study of TENEO 317 Model 2 (1.28 US) Excimer Laser in Myopic Astigmatism, sponsored by Bausch & Lomb Incorporated. Not yet recruiting. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Astigmatism by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Astigmatism · Bausch Health Companies Inc..
Among the 23 studies in Astigmatism by Bausch Health Companies Inc., this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 with no phase, and was the 23rd registered.
418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.
Browse Astigmatism studies →1 of the 23 studies in Astigmatism by Bausch Health Companies Inc. is open now.
Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 32 is below the median of 55 across 326 interventional studies indexed under Astigmatism.
Median enrollment 60 across the 19 interventional studies, 100 across the 4 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
1 of the studies in Astigmatism by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07377474Bausch & Lomb IncorporatedA Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Astigmatism by Bausch Health Companies Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a multicenter, prospective, open label, non-randomized, single arm study evaluating the safety and effectiveness of the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser when used in LASIK surgery to treat myopia or myopic astigmatism. One or both eyes of a subject may be treated so long as both eyes meet all inclusion/exclusion requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ocular conditions that may predispose the subject to future complications, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: TENEO 317 Model 2 (1.28 US) Excimer Laser
Surgery to Treat Myopia or Myopic Astigmatism with Sphere between 0.00D and -1.00D
The percentage of eyes that achieve predictability (attempted versus achieved) of MRSE within ± 0.50 D
Time frame: Assessed for approximately 12 months
The percentage of eyes that achieve predictability (attempted versus achieved) of MRSE within ± 1.00 D
Time frame: Assessed for approximately 12 months
The percentage of eyes that achieve a UDVA of 20/40 or better
Time frame: Assessed for approximately 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Sep 2027, 17 months later.
Of 106 industry-sponsored interventional studies with no phase under Astigmatism, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 17 months is above that.
Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.